These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

799 related articles for article (PubMed ID: 10912744)

  • 1. Hyperapobetalipoproteinemia with compositional abnormality of LDL and IDL, a characteristic lipoprotein alteration in essential hypertension.
    Ryomoto KI; Suzuki M; Kanazawa A; Hasegawa M; Kimura Y; Yamamura T; Harano Y
    Am J Hypertens; 2000 Jun; 13(6 Pt 1):617-24. PubMed ID: 10912744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperbetalipoproteinemia with small low-density lipoprotein, a characteristic disorder of lipoprotein in essential hypertension.
    Ikeda K; Suzuki M; Ikebuchi M; Hara Y; Tsushima M; Yamamoto A; Harano Y
    J Diabetes Complications; 1995; 9(4):227-9. PubMed ID: 8573733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
    Guerin M; Egger P; Soudant C; Le Goff W; van Tol A; Dupuis R; Chapman MJ
    Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.
    Watts GF; Barrett PH; Ji J; Serone AP; Chan DC; Croft KD; Loehrer F; Johnson AG
    Diabetes; 2003 Mar; 52(3):803-11. PubMed ID: 12606523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VLDL and IDL apolipoprotein B-100 kinetics in familial hypercholesterolemia due to impaired LDL receptor function or to defective apolipoprotein B-100.
    Zulewski H; Ninnis R; Miserez AR; Baumstark MW; Keller U
    J Lipid Res; 1998 Feb; 39(2):380-7. PubMed ID: 9507998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of age on the metabolism of VLDL, IDL, and LDL apolipoprotein B-100 in men.
    Millar JS; Lichtenstein AH; Cuchel M; Dolnikowski GG; Hachey DL; Cohn JS; Schaefer EJ
    J Lipid Res; 1995 Jun; 36(6):1155-67. PubMed ID: 7665994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages.
    Milosavljevic D; Griglio S; Le Naour G; Chapman MJ
    Atherosclerosis; 2001 Mar; 155(1):251-60. PubMed ID: 11223449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abnormalities of VLDL, IDL, and LDL characterize insulin-dependent diabetes mellitus.
    Winocour PH; Durrington PN; Bhatnagar D; Ishola M; Arrol S; Mackness M
    Arterioscler Thromb; 1992 Aug; 12(8):920-8. PubMed ID: 1637789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An increased number of very-low-density lipoprotein particles is strongly associated with coronary heart disease in Japanese men, independently of intermediate-density lipoprotein or low-density lipoprotein.
    Koba S; Hirano T; Sakaue T; Takeuchi H; Adachi M; Katagiri T
    Coron Artery Dis; 2002 Aug; 13(5):255-62. PubMed ID: 12394649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of hepatic lipase in intermediate-density lipoprotein and small, dense low-density lipoprotein formation in hemodialysis patients.
    Oi K; Hirano T; Sakai S; Kawaguchi Y; Hosoya T
    Kidney Int Suppl; 1999 Jul; 71():S227-8. PubMed ID: 10412783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterogeneous properties of intermediate- and low-density lipoprotein subpopulations.
    Srisawasdi P; Vanavanan S; Rochanawutanon M; Pornsuriyasak P; Tantrakul V; Kruthkul K; Kotani K
    Clin Biochem; 2013 Oct; 46(15):1509-15. PubMed ID: 23830843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overproduction of small very low density lipoproteins (Sf 20-60) in moderate hypercholesterolemia: relationships between apolipoprotein B kinetics and plasma lipoproteins.
    Gaw A; Packard CJ; Lindsay GM; Griffin BA; Caslake MJ; Lorimer AR; Shepherd J
    J Lipid Res; 1995 Jan; 36(1):158-71. PubMed ID: 7706941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apolipoprotein B metabolism and the distribution of VLDL and LDL subfractions.
    Packard CJ; Demant T; Stewart JP; Bedford D; Caslake MJ; Schwertfeger G; Bedynek A; Shepherd J; Seidel D
    J Lipid Res; 2000 Feb; 41(2):305-18. PubMed ID: 10681415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma markers of cholesterol homeostasis and apolipoprotein B-100 kinetics in the metabolic syndrome.
    Chan DC; Watts GF; Barrett PH; O'Neill FH; Thompson GR
    Obes Res; 2003 Apr; 11(4):591-6. PubMed ID: 12690090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of bezafibrate on very low density lipoprotein (VLDL), intermediate density lipoprotein (IDL), and low density lipoprotein (LDL) composition in type 1 diabetes associated with hypercholesterolaemia or combined hyperlipidaemia.
    Winocour PH; Durrington PN; Bhatagnar D; Ishola M; Mackness M; Arrol S; Anderson DC
    Atherosclerosis; 1992 Mar; 93(1-2):83-94. PubMed ID: 1596307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of simvastatin on the number and composition of apoproteinB-containing lipoproteins in hypercholesterolemia: analysis of apoproteinB in each lipoprotein fraction by highly sensitive latex method.
    Ikeda Ryomoto K; Suzuki M; Tsushima M; Yamamoto A; Harano Y
    Endocr J; 1996 Oct; 43(5):469-75. PubMed ID: 8980885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of mild to moderately elevated triglycerides on low density lipoprotein subfraction concentration and composition in healthy men with low high density lipoprotein cholesterol levels.
    Halle M; Berg A; Baumstark MW; König D; Huonker M; Keul Joseph
    Atherosclerosis; 1999 Mar; 143(1):185-92. PubMed ID: 10208494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abnormal lipid and apolipoprotein composition of major lipoprotein density classes in patients with chronic renal failure.
    Attman PO; Alaupovic P; Tavella M; Knight-Gibson C
    Nephrol Dial Transplant; 1996 Jan; 11(1):63-9. PubMed ID: 8649654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-density lipoprotein particle size, triglyceride-rich lipoproteins, and glucose tolerance in non-diabetic men with essential hypertension.
    Rubies-Prat J; Ordóñez-Llanos J; Martin S; Blanco-Vaca F; Molina L; Goday A; Pedro-Botet J
    Clin Exp Hypertens; 2001 Aug; 23(6):489-500. PubMed ID: 11478431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB-containing lipoproteins: implications for the pathophysiology of apoB production.
    Arad Y; Ramakrishnan R; Ginsberg HN
    J Lipid Res; 1990 Apr; 31(4):567-82. PubMed ID: 2351867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.